Pfizer posts detailed phase 3 data on its Dupixent rival by Nick Paul Taylor Saturday, October 12, 2019 The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.
Chasing AbbVie, Gilead files for approval of filgotinib in Japan by Nick Paul Taylor Tuesday, October 8, 2019 The submission moves Gilead a step closer to selling the Galapagos-partnered drug to rheumatoid arthritis patients in the country.
Pfizer's JAK inhibitor hits the mark in another eczema trial by Amirah Al Idrus Friday, September 27, 2019 Pfizer’s JAK inhibitor cleared patients’ skin and improved atopic dermatitis symptoms in a second phase 3 study.
Concert's alopecia drug sails through phase 2 by Amirah Al Idrus Tuesday, September 3, 2019 Two dose levels of Concert's alopecia drug beat placebo in phase 2, teeing it up to enter phase 3 in 2020.
Genentech’s inhaled JAK1 inhibitor shows promise in asthma by Angus Liu Wednesday, November 21, 2018 Genentech's lung-restricted JAK1 inhibitor reduced lung inflammation and airway symptoms in rodent models of asthma.
Concert’s alopecia drug hits phase 2 endpoint with more data to come by Amirah Al Idrus Monday, November 12, 2018 Concert Pharmaceuticals’ alopecia drug reduced disease severity in nearly half of the patients who received a higher dose.
Gilead, Galapagos’ filgotinib aces first phase 3 by Nick Paul Taylor Wednesday, September 12, 2018 The data suggest filgotinib is safe and as effective as JAK rivals including AbbVie’s upadacitinib, setting the stage for a four-way commercial scrap.
